Bausch & Lomb Corp (BLCO) company profile
Close on Nov 17, 2026Market cap $7.45BP/E –Yield –
About Bausch & Lomb
Ophthalmic Goods, SIC 3851
Bausch + Lomb Corporation develops, manufactures, and markets eye health products worldwide across three operating segments: Vision Care, Pharmaceuticals, and Surgical. Its Vision Care unit provides contact lenses, including daily disposables and specialty lenses, as well as consumer eye care items such as lens care solutions, over-the-counter eye drops, and nutritional supplements. The Pharmaceuticals division offers prescription and generic medications for ocular conditions, including dry eye disease, glaucoma, ocular hypertension, and post-operative inflammation. The Surgical segment supplies ophthalmic surgical devices, diagnostic and procedural equipment, intraocular lenses, delivery systems, and surgical instruments. The company provides its products to patients, consumers, eye care professionals, optometrists, physicians, and retail partners.
The company operates globally with approximately 13,000 employees and maintains a business presence across approximately 100 countries. Its research and development network comprises 13 facilities with around 900 dedicated personnel working on clinical programs worldwide. The provided text does not identify the location of its corporate headquarters.
Summary of the business section of Bausch & Lomb's latest annual report, written by StockData.
Company profile
Company
- Legal name
- Bausch & Lomb Corp
- Founded
- 1853
- Headquarters
- Vaughan, A6
- Address
- 520 Applewood Crescent L4K 4B4
- Phone
- (908) 541-5456
- Website
- bausch.com
- Employees
- 13,000, Dec 31, 2025
- Industry
- Ophthalmic Goods
- Fiscal year ends
- December 31
- Auditor
- PricewaterhouseCoopers LLP, Florham Park, New Jersey
Stock & identifiers
- Ticker
- BLCO
- Exchange
- NYSE
- IPO date
- May 6, 2022
- Shares outstanding
- 357M, Oct 21, 2026
- Public float
- $556.99M, Jun 30, 2025
- Filer category
- Large accelerated filer
- SEC CIK
- 1860742
- CUSIP
- 071705107
- ISIN
- US0717051074
- FIGI
- BBG014KG1L68
- Share class FIGI
- BBG014KG1GY8
- LEI
- 549300NY6OZM39SO6475
- EIN
- 00-0000000
Executives and directors
Officers and directors who filed ownership reports (Forms 3, 4, 5) in the last two years
| Name | Position | Shares owned |
|---|---|---|
| Brent L. Saunders | Chairman of the Board and CEO, Director | 974,158 |
| Frederick Munsch | SVP, Controller and CAO | 45,831 |
| Andrew J. Stewart | President, GPIC | 103,211 |
| Luc Bonnefoy | President, Surgical | 103,801 |
| A. Robert D. Bailey | EVP & Chief Legal Officer | 264,241 |
| Sam Eldessouky | EVP and CFO | 393,527 |
| Yehia Hashad | EVP of R&D and CMO | 187,350 |
| Eduardo Alfonso | Director | 32,197 |
| John Paulson | Director | 90,948 |
| Russel C. Robertson | Director | 95,516 |
| Thomas Appio | Director | 27,583 |
| Laurence E. Paul | Director | 11,776 |
| Robert J. Chersi | Director | 11,776 |
| Barbara Trebbi | Director | 11,776 |
| Eschenbach Andrew C. Von | Director | 63,733 |
| Thomas W. Ross Sr. | Director | 85,233 |
| Sarah B. Kavanagh | Director | 69,541 |
| Karen Ling | Director | 61,518 |
| Steven H. Collis | Director | 42,003 |
| Nathalie D. Bernier | Director | 85,505 |
| Brett Icahn | Director | 61,147 |
| Gaoxiang Hu | Director | 61,147 |
CEO pay and shareholder return
Pay versus performance table from the proxy statement
| Fiscal year | CEO total pay | CEO pay actually paid | Other executives (avg) | Value of $100 invested | Peer group |
|---|---|---|---|---|---|
| FY2025 Brenton LSaunders | $32.19M | $27.23M | $3.47M | $85 | $91 |
| FY2025 Joseph CPapa | $0 | $0 | $3.47M | $85 | $91 |
| FY2024 Brenton LSaunders | $23.86M | $21.41M | $5.24M | $90 | $94 |
| FY2024 Joseph CPapa | $0 | $0 | $5.24M | $90 | $94 |
| FY2023 Brenton LSaunders | $45.31M | $36.16M | $4.32M | $85 | $103 |
| FY2023 Joseph CPapa | $9.53M | $5.64M | $4.32M | $85 | $103 |
“Actually paid” adjusts reported pay for changes in the value of equity awards. Shareholder return assumes $100 invested at the start of the measurement period, as disclosed by the company.
Executive compensation, fiscal 2025
Summary compensation table from the latest proxy statement
| Executive | Salary | Bonus | Stock awards | Option awards | Incentive pay | Other | Total | vs. prior year |
|---|---|---|---|---|---|---|---|---|
| Brenton L. Saunders Chairman of the Board and Chief Executive Officer | $1.60M | – | $23.78M | $2.80M | $4.00M | $15.75K | $32.19M | +35% |
| Sam A. Eldessouky Executive Vice President and Chief Financial Officer | $777.98K | $250.00K | $2.51M | $660.00K | $744.00K | $15.75K | $4.96M | -27% |
| A. Robert D. Bailey Executive Vice President and Chief Legal Officer | $767.94K | – | $1.71M | $450.00K | $673.20K | $27.25K | $3.63M | -34% |
| Yehia Hashad, M.D. Executive Vice President of Research & Development and Chief Medical Officer | $726.12K | – | $1.07M | $280.00K | $700.80K | $15.75K | $2.79M | -38% |
| Andrew J. Stewart President, Global Pharmaceuticals and International Consumer | $629.08K | – | $990.63K | $260.00K | $604.80K | $15.75K | $2.50M | -39% |
Stock and option awards are grant-date fair values, not realized pay. “Other” includes pension value changes and all other compensation. Source proxy statement.
IPO
From the final prospectus (Form 424B4) and the first day of trading
Offering
- Type
- Initial public offering
- Final prospectus filed
- May 6, 2022
- Offer price
- $18.00
- Exchange
- NYSE
- First trading day
- May 6, 2022
- First-day close
- $20.00+11.1%
- Lock-up ends (est.)
- Nov 2, 2022
“The initial public offering price is $18.00 per common share.”
Lock-up end is estimated as 180 days after the first trading day; the prospectus sets the actual terms.
Employees
Headcount reported in annual reports
“As of December 31, 2025, we had approximately 13,000 employees, which included approximately 7,000 in production, 4,200 in sales and marketing, 900 in general and administrative positions and 900 in R&D.”
Corporate history
Events identified from SEC filings
| Date | Event | Details |
|---|---|---|
| Sep 29, 2023 | Acquisition / sale | Completion of acquisition or disposition of assets (8-K Item 2.01) |
| May 6, 2022 | IPO | Initial public offering priced (424B4 prospectus) |
| May 5, 2022 | Listing | Registration of securities on an exchange (Form 8-A) |
See a number that looks wrong?